 Currently, based on the successful pioneer work of Dr Nilsson and her colleagues in Sweden that started in the late 1950s, prophylaxis is recommend as the standard of care for boys with severe haemophilia by WHO and WFH. 2 The efficacy and safety of prophylaxis in preventing bleeds and arthropathy in patients with hemophilia has been confirmed in well-designed clinical studies.3,4,5To keep the factor level above 1, the standard dosage for patients with severe hemophilia A is 20-40 Units kginfusion average 30 Units kg 6 every other day or three times a week. This dosage has a very high consumption of factor, up to 5000-6000 international unitIUkgyear. 7 The high consumption of factor and cost present a major barrier to use the standard prophylaxis in many countries particularly in the developing world. 8 Many families are looking forward to standard prophylaxis to reducing bleeding episodes, stop or slow the deterioration of joint disease in their sons with severe hemophilia and thus improving their quality of life QoL. But in China the majority of boys with severe hemophilia A cannot afford the high costs of standard prophylaxis .They can only pay for on-demand treatment or low-dose prophylaxis. But after the Advate Patient Assistance ProgramGolden Key was launched in 24 Apr 2014 in Nanjing China, the affordability of patients was solved and many patients will get more chance to receive standard prophylaxis. 